# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Balaji Prasad maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $260 to $230.
The analysis screened S&P 500 stocks that show an inverse correlation to Nvidia over a month and year period, following Nvi...
Scout Clean Energy (Scout), a Colorado-based renewable energy developer-owner-operator, is pleased to announce they have signed...
Piper Sandler analyst David Westenberg reiterates Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $220 ...
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.
Zoetis' Solensia and Librela, pioneering arthritis treatments for pets. Despite recent concerns, Zoetis defends their safet...